Animalcare is excited to be attending BVA and LVS again in 2026.

Did you see us at BVA Live and London Vet Show last year?

Our team showcased their passion for Daxocox® and it’s place in the veterinary industry with a bright and bold campaign.

Be Their Hero With Daxocox®!

The focus of the campaign was to highlight the importance of owner adherence and the relationship between pet and owner to really help drive treatment for Osteoarthritis.

We had some amazing engagement from people all across the veterinary profession and it was great to see how well the product was received and the excitement around it’s pharmacology. Daxocox®, the first and only weekly oral NSAID for the treatment of pain and inflammation associated with osteoarthritis in dogs, seeks to help owners with convenient and effective long-term pain control for their dog, while providing veterinary professionals with tools in the armoury to assist with the long-term management of OA.

Will you be stopping by our stand in 2026? Stay tuned for more details!

Daxocox® – Active substance: Enflicoxib UK POM-V, Legal category: POM-V, 15mg UK Vm 32742/5001, NI EU/2/21/270/001-007, 30mg UK Vm 32742/5002, NI EU/2/21/270/008-014, 45mg UK Vm 32742/5003, NI EU/2/21/270/015-021, 70mg UK Vm 32742/5004, NI EU/2/21/270/022-028, 100mg UK Vm 32742/5005, NI EU2/21/270/029-035. Daxocox® is indicated for the reduction of pain associated with osteoarthritis in dogs and contains Enflicoxib.
Please refer to the SPC or package leaflet for full product information including side effects, precautions, warnings and contra-indications before use. Prescription decisions are for the person issuing the prescription alone
USE MEDICINES RESPONSIBLY.
Daxocox® is a registered trademark of Animalcare Group Plc